News from betagenon ab A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

17 Aug, 2020, 14:30 BST Start of bridging pharmacokinetic and safety clinical trial of a novel solid pharmaceutical composition of AMPK activator O304

In previous Phase I and Phase IIa clinical trials in healthy subjects and in type 2 diabetics, the small molecule AMPK activator compound O304 was...


20 Jan, 2020, 03:05 GMT China-Based Ivy Capital Invests in Betagenon's Clinical Stage AMPK Activator Program

Balticgruppen Bio, the Umeå based Biotech company focused on development of AMPK activator compounds, operating under the trademark Betagenon, has...


03 Jan, 2019, 09:44 GMT Dr. Jan M. Lundberg, Former Head of R&D at AstraZeneca and Eli Lilly has Joined Betagenon's Board of Directors

"Jan's executive industrial experience as head of R&D at two major pharmaceutical companies, and his involvement the discovery, development and...


18 May, 2018, 13:39 BST AMPK Activator O304 A Novel Potential Treatment for Diabetic Kidney Disease

Diabetic kidney disease Globally ~40% of type 2 diabetes (T2D) patients develop diabetic kidney disease (DKD), and diabetes is the leading cause of...


02 Nov, 2017, 10:21 GMT Betagenon/Baltic Bio Announces Positive Results From a 28-day Phase IIa Trial of the First-in-class AMPK Activator O304 in Type 2 Diabetics

O304 reduces significantly fasting plasma glucose (FPG) in type 2 diabetics The main study results are not yet finalized. Review of the initial data...